Dave Coulier’s new tongue cancer diagnosis raises questions about whether it’s linked to his prior lymphoma. Experts explain the risks, causes, and why second primary cancers can occur.

“LYMPHIR is an important new treatment option for the CTCL community, and its launch marks the beginning of a new chapter for Citius Oncology,” Leonard Mazur, chairman and CEO of Citius Oncology and Citius Pharmaceuticals, said in a statement.

Follicular lymphoma (FL) is the second most frequent subtype of non-Hodgkin lymphoma, a cancer of the immune system. Although the disease is typically incurable, many cases progress slowly and do not require immediate treatment.

The US Food and Drug Administration (FDA) has accepted the new drug application (NDA) for BeOne Medicines’ B-cell lymphoma 2 (BCL2) inhibitor, sonrotoclax, and granted it priority review for use in treating adults with relapsed or refractory mantle cell lymphoma (R/R MCL).